Skye Becomes a Shell for Redx: $125 Million Deal Hands Control to UK Fibrosis Company
Skye Bioscience acquires Redx Pharma via UK scheme of arrangement. Combined company Fibrx focuses on RXC008 for Crohn’s fibrosis. Skye holders get only 5.38%.
/ 1648 items
#XY↓
Vera Therapeutics Shares Rally After Strong Interim eGFR Results Surface in FDA Review
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.
Jefferies Upgrades Minerva Neurosciences to Buy on Clearer FDA Path for Roluperidone
Minerva gained analyst support as its schizophrenia drug advances in Phase 3, backed by new funding and a clearer FDA path.
Capricor Soars After Cantor Upgrade as FDA Path for Deramiocel Becomes Clearer
Analyst upgrade sends Capricor shares higher after company outlines BLA amendment path for deramiocel focused on upper-limb function.
Valneva’s Lyme Disease Vaccine Candidate Clears Key EMA Hurdle
Valneva shares surge after EMA validates its Lyme disease vaccine candidate developed with Pfizer. Phase 3 trial showed over 70% efficacy.
Morgan Stanley Starts Coverage of Achieve Life Sciences at Overweight with $13 Price Target
Achieve's smoking-cessation drug impressed analysts with strong trial results, putting the company on track for possible FDA approval in 2027.